Eli Lilly Invests $1.8 Billion in Irish Drug Production
Eli Lilly is investing $1.8 billion in Ireland to enhance production capabilities for its Alzheimer's treatment and obesity drugs. This investment is part of a broader commitment of over $20 billion in manufacturing since 2020.
| Score | Value |
|---|---|
Scale | 7 |
Novelty | 6 |
Positivity | 6 |
Reliability | 8 |
Actionability | 2 |
Society | 7 |
Journalism | 4 |
Highlights
- Eli Lilly is investing $1.8 billion to expand production in Ireland for its Alzheimer's treatment and weight-loss drugs.
- The company's Alzheimer's drug, Kisunla, received U.S. FDA approval in July.
- Eli Lilly has committed over $20 billion to manufacturing investments in the U.S. and Europe since 2020.
- The investment includes $800 million for a facility in Kinsale and $1 billion for a facility in Limerick.
- Demand for Lilly's weight-loss drug Zepbound has outpaced supply for most of this year.